View in EDS HTML Full Text PDF Full Text

Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.

Saved in:
Bibliographic Details
Title: Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
Authors: Crowley, Jeffrey J.1 (AUTHOR) crowley415@aol.com, Langley, Richard G.2 (AUTHOR), Gordon, Kenneth B.3 (AUTHOR), Pinter, Andreas4 (AUTHOR), Ferris, Laura K.5 (AUTHOR), Rubant, Simone6 (AUTHOR), Photowala, Huzefa7 (AUTHOR), Xue, Zhenyi7 (AUTHOR), Wu, Tianshuang7 (AUTHOR), Zhan, Tianyu7 (AUTHOR), Beeck, Stefan7 (AUTHOR), Shah, Megha7 (AUTHOR), Warren, Richard B.8 (AUTHOR)
Source: Dermatology & Therapy. Feb2022, Vol. 12 Issue 2, p561-575. 15p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:21938210
DOI:10.1007/s13555-021-00679-6